Abstract
This study reports for the first time the AbaR4-type resistance island with the blaOXA-23 gene in two carbapenem-resistant A. nosocomialis isolates from South Korea and Thailand.
TEXT
OXA-23, an acquired class D β-lactamase with carbapenemase activity, confers carbapenem resistance in Acinetobacter baumannii. The presence of the blaOXA-23 gene has increasingly been reported worldwide and has emerged as a serious threat (5). Although several transposons, such as Tn2006, Tn2007, and Tn2008, have been identified as genetic structures harboring the blaOXA-23 gene, Tn2006 is part of the ISAba1-linked AbaR4-type resistance island of A. baumannii related to clonal dissemination of the carbapenem-resistant A. baumannii European clone II, ST92, in many countries (5). Acinetobacter radioresistens was identified as a source of the blaOXA-23-like genes (8), but an AbaR4-type resistance island including the blaOXA-23-like gene has not been found in species other than A. baumannii. In this article, we report the AbaR4-type resistance island with the blaOXA-23 gene in two Acinetobacter nosocomialis (formerly Acinetobacter genomospecies 13TU) isolates.
In a molecular epidemiology study of Acinetobacter sp. isolates from Asian countries, we found two A. nosocomialis isolates harboring the blaOXA-23-like gene, which was identified by multiplex PCR (11). This species was identified using sequences of 16S rRNA and partial rpoB genes (2). The sequences displayed 100% similarity to the reference strains of A. nosocomialis LMG 10619T and RUH503 in the 16S rRNA and rpoB gene analyses, respectively. Two blaOXA-23-positive A. nosocomialis isolates, K08-39 and Th01-06, were isolated from South Korea and Thailand, respectively. Both were isolated from patients who developed hospital-acquired pneumonia: K08-39 from the endotracheal aspirate and Th01-06 from the sputum. In vitro susceptibility testing was performed by measuring the MIC using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines (1). K08-39 from South Korea and Th01-06 from Thailand were resistant to both imipenem and meropenem (Table 1). K08-39 showed very high MICs for imipenem and meropenem (>64 and 64 mg/liter, respectively), while Th01-06 did not. K08-39 was susceptible to antimicrobial agents other than carbapenem, but Th01-06 was resistant to piperacillin-tazobactam and intermediate in resistance to cefepime.
Table 1.
Characteristic | Value or description for isolatea |
|
---|---|---|
K08-39 | Th01-06 | |
Species | A. nosocomialis | A. nosocomialis |
Locality | South Korea | Thailand |
Source | Endotrachial aspirate | Sputum |
MIC of antimicrobial agent, mg/liter (susceptibility) | ||
Gentamicin | 2 (S) | 0.25 (S) |
Ceftazidime | 4 (S) | 2 (S) |
Cefotaxime | 4 (S) | 8 (S) |
Cefepime | 2 (S) | 16 (I) |
Ciprofloxacin | 0.12 (S) | 0.12 (S) |
Imipenem | >64 (R) | 16 (R) |
Meropenem | 64 (R) | 16 (R) |
Trimethoprim-sulfamethoxazole | 0.12, 2.37 (S) | 2, 38 (S) |
Piperacillin-tazobactam | ≤0.25, 4 (S) | 256, 4 (R) |
Colistin | 0.5 (S) | 1 (S) |
Polymyxin B | 0.5 (S) | 1 (S) |
R, resistant; I, intermediate; S, susceptible.
The comM gene was evaluated for the presence of a transposon containing the blaOXA-23 gene. Both the Th01-06 and K08-39 isolates failed to produce a comM amplicon, indicating the interruption of the comM gene. They were PCR positive for the AbaR-comM junction, confirming the presence of an AbaR-type resistance island. The structure of the AbaR-type resistance islands was determined by several PCR procedures and sequencing using previously published primers (9, 10). Both showed the AbaR4 type, although their subtypes were also identified (see Fig. S1 in the supplemental material). While a primer set spanning tniB-tniE produced a 388-bp amplicon in the K08-39 isolate (referred to as the AB210 type), a 3,238-bp amplicon was produced by the same primer set in the Th01-06 isolate (referred to as the D36 type). In K08-39, the AB210 type, the tniB gene was 500 bp in size, while the tniD gene was absent. In Th01-06, the D36 type, however, the tniB gene was 921 bp in size, while the tniD gene was present. These AbaR4-type resistance islands have been identified nearly exclusively in the global clone II (GC II; formerly European clone II) of A. baumannii (9, 10), which is the most frequently identified clone in Asian countries, including South Korea (6). Thus, we hypothesize that AbaR4-type resistance islands, including the blaOXA-23 gene in A. nosocomialis, have been transferred from A. baumannii GC II clones. Although the resistance islands of both isolates belonged to the AbaR4 type, they might have been transferred independently because they are of different subtypes and different localities.
The expression of OXA-23 in the two A. nosocomialis isolates was evaluated by quantitative reverse transcription-PCR (qRT-PCR) and normalized against the housekeeping gene rpoB. To compare the expression of OXA-23, two blaOXA-23-positive carbapenem-resistant, one blaOXA-23-negative carbapenem-resistant, and one blaOXA-23-negative carbapenem-susceptible A. baumannii isolate were also included in the qRT-PCR. Both blaOXA-23-positive A. nosocomialis isolates showed high mRNA levels of OXA-23 (see Fig. S2 in the supplemental material). Since we know that the blaOXA-23 gene confers resistance to carbapenems in A. baumannii isolates, the high expression of blaOXA-23 genes in the two A. nosocomialis isolates likely contributes to the resistance to carbapenems as well.
A. nosocomialis, which was long referred to as Acinetobacter genomospecies 13TU, belongs to the A. calcoaceticus-A. baumannii (Acb) complex or A. baumannii group along with Acinetobacter pittii (formerly Acinetobacter genomospecies 3) because they could not be differentiated easily by phenotypic or biochemical methods. A. nosocomialis is the second-most-frequent species isolated from blood among the genus Acinetobacter in South Korea and displays a low carbapenem resistance rate but a high polymyxin resistance rate, unlike A. baumannii (6). In our recent study, two carbapenem-resistant A. nosocomialis isolates from South Korea contained the blaSIM-1 gene, which has been identified in other Acinetobacter species, including A. baumannii (3, 4, 7, 12). Although blaOXA-23 has been identified in A. radioresistens and Acinetobacter baylyi (9, 12), it was first identified in A. nosocomialis. Thus, our findings in this study suggest that interspecies transfer of the resistance island may occur, which could contribute to the dissemination of the antimicrobial-resistant isolates of Acinetobacter species.
Supplementary Material
ACKNOWLEDGMENTS
Acinetobacter isolates used in this study were obtained from the Asian Bacterial Bank (ABB) of the Asia Pacific Foundation for Infectious Diseases (APFID) (Seoul, South Korea).
This study was supported by a Samsung Biomedical Research Institute grant (no. BA-90012).
Footnotes
Published ahead of print 11 June 2012
Supplemental material for this article may be found at http://aac.asm.org/.
REFERENCES
- 1. Clinical and Laboratory Standards Institute (CLSI) 2011. Performance standards for antimicrobial susceptibility testing, 19th informational supplement, M100-S21. CLSI, Wayne, PA [Google Scholar]
- 2. Ko KS, et al. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60:1163–1167 [DOI] [PubMed] [Google Scholar]
- 3. Lee K, et al. 2010. Characteristics of clinical isolates of Acinetobacter genomospecies 10 carrying two different metallo-beta-lactamases. Int. J. Antimicrob. Agents 36:259–263 [DOI] [PubMed] [Google Scholar]
- 4. Lee K, et al. 2005. Novel acquired metallo-beta-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother. 49:4485–4491 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Mugnier PD, Poirel L, Naas T, Nordmann P. 2010. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg. Infect. Dis. 16:35–40 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Park YK, et al. 2012. Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years. J. Med. Microbiol. 61:71–79 [DOI] [PubMed] [Google Scholar]
- 7. Park YK, Jung SI, Park KH, Kim SH, Ko KS. 2012. Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea. Int. J. Antimicrob. Agents 39:81–85 [DOI] [PubMed] [Google Scholar]
- 8. Poirel L, Figueiredo S, Cattoir V, Carattoli A, Nordmann P. 2008. Acinetobacter radioresistens as a silent source of carbapenem resistant for Acinetobacter spp. Antimicrob. Agents Chemother. 52:1252–1256 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Post V, White PA, Hall RM. 2010. Evolution of AbaR-type genomic resistance islands in multiply antibiotic-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65:1162–1170 [DOI] [PubMed] [Google Scholar]
- 10. Turton JF, Baddal B, Perry C. 2011. Use of accessory genome for characterization and typing of Acinetobacter baumannii. J. Clin. Microbiol. 49:1260–1266 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Woodford N, et al. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27:351–353 [DOI] [PubMed] [Google Scholar]
- 12. Zhou Z, et al. 2011. Clinical carbapenem-resistant Acinetobacter baylyi strain coharboring blaSIM-1 and blaOXA-23 from China. Antimicrob. Agents Chemother. 55:5347–5349 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.